A major route of transmission of Visna/maedi virus (VMV), an ovine lentivirus, is thought to be via the respiratory tract, by inhalation of either cell-free or cell-associated virus. In previous studies, we have shown that infection via the lower respiratory tract is much more efficient than via upper respiratory tissues (T. N. McNeilly, P. Tennant, L. Lujan, M. Perez, and G. D. Harkiss, J. Gen. Virol. 88:670-679, 2007). Alveolar macrophages (AMs) are prime candidates for the initial uptake of virus in the lower lung, given their in vivo tropism for VMV, abundant numbers, location within the airways, and role in VMV-induced inflammation. Furthermore, AMs are the most likely cell type involved in the transmission of cell-associated virus. In this study, we use an experimental in vivo infection model that allowed the infection of specific segments of the ovine lung. We demonstrate that resident AMs are capable of VMV uptake in vivo and that this infection is associated with a specific up-regulation of AM granulocyte-macrophage colony-stimulating factor mRNA expression (P < 0.05) and an increase in bronchoalveolar lymphocyte numbers (P < 0.05), but not a generalized inflammatory response 7 days postinfection. We also demonstrate that both autologous and heterologous VMV-infected AMs are capable of transmitting virus after lower, but not upper, respiratory tract instillation and that this transfer of virus appears not to involve the direct migration of virus-infected AMs from the airspace. These results suggest that virus is transferred from AMs into the body via an intermediate route. The results also suggest that the inhalation of infected AMs represents an additional mechanism of virus transmission.
Visna/maedi virus (VMV) is a member of the lentivirus subgroup of retroviruses that cause lymphoid interstitial pneumonia, encephalitis, arthritis, and mastitis in sheep (40, 41) . The main routes of transmission of VMV are thought to be through the ingestion of infected colostrum and/or milk or through the inhalation of infected respiratory secretions (6, 34) . We recently have demonstrated that a major route of respiratory transmission is likely via the uptake of cell-free VMV in the lower respiratory tract (33) , although the initial target cells for cell-free VMV at this site were not identified.
It is known that VMV exhibits strong tropism for alveolar macrophages (AMs) in vivo in naturally infected sheep (7, 9, 18, 30) and is present in AMs following experimental infection from 11 days after lung instillation (19, 42) . In addition, AMs are present in large numbers within the lower lung airspace. Consequently, AMs represent a likely initial target for VMV uptake in the lower respiratory tract and therefore may play a key role in the respiratory transmission of VMV.
Assuming AMs play a role in respiratory transmission of VMV, virus taken up by resident AMs must be transmitted from these cells within the lung airspace into the body. As yet there is no information regarding the transfer of virus from VMV-infected AMs in the airspace to adjacent lung tissue. Transfer of virus from infected AMs also may be relevant with regard to heterologous cell-associated virus transmission, as it is possible that respiratory transmission is mediated by the inhalation of both cell-free and cell-associated VMV derived from infected individuals. However, as yet there is no direct evidence that cell-associated virus transmission occurs between sheep.
If virus transfer occurs from VMV-infected AMs in the airspace entering into the body, it is likely to involve the infection of the draining lymph nodes, which are thought to be important initial sites of infection (5) . This transfer may involve an indirect route or may occur by direct migration of infected AMs to the lymph node, as there is evidence to suggest that AMs are capable of migrating from the alveolar space into the regional lymphoid tissue (12, 23, 27) .
AMs also have been implicated as the main cell type involved in VMV-induced lung inflammation, primarily by the dysregulation of cytokine gene expression and subsequent recruitment of inflammatory cells (29, 50) . It is possible that AMs mediate a similar inflammatory response during early VMV infection in vivo, as suggested by the observed up-regulation of interleukin-8 (IL-8) expression by AMs within 48 h of in vitro infection (28) . This may have implications for the enhancement of virus uptake, as a number of proinflammatory cytokines have been shown to enhance VMV replication in AMs and other macrophages in vitro (15, 50) , and generalized inflammation is likely to result in the recruitment of VMV target cells, namely, macrophages and dendritic cells (DCs) (7, 36) .
In this study, we investigated the role of AMs in initial VMV uptake using a segmental lung model system. We demonstrate that AMs are capable of the uptake of cell-free virus in vivo and that early VMV infection is associated with a specific up-regulation of AM granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA expression in the absence of a generalized inflammatory response. Furthermore, we demonstrate that both autologous and heterologous VMV-infected AMs are capable of transmitting virus into the body after instillation into the lower lung, and that the transfer of virus from AMs in the lower lung to regional lymph nodes appears not to involve AM migration.
MATERIALS AND METHODS
Virus propagation and titration. Low-passage VMV strain EV1 (38) was propagated and titrated on ovine skin cells (OSCs) as described previously (33) . Mock-infected medium controls were generated by culturing the same OSCs as those used for virus propagation, but without the addition of virus. Supernatants were collected on the same day as viral supernatants and processed identically.
BAL. Bronchoalveolar lavage (BAL) was performed either under general anesthesia or at postmortem as described previously (11) . Lavage fluid subsequently was centrifuged at 400 ϫ g for 7 min, and the resultant cell pellets were resuspended in sterile phosphate-buffered saline (PBS). Cells were counted using a Neubauer hemocytometer before cytocentrifuge preparation, AM purification, and VMV infection.
Differential cytology of BAL cells. Cytocentrifuge slides were stained using Leishman's stain, and differential cell counting was performed on 500 cells. Cells were classified as macrophages, neutrophils, lymphocytes, eosinophils, mast cells, or other cells according to standard morphological criteria. Total numbers of BAL cells/milliliter of BAL fluid and the percentage of each cell type within the BAL cell population were compared to previously published normal limits (11) .
Purification of AMs and RNA extraction. The purification of AMs was based on a procedure described previously (28, 50) that relies on the preferential adherence of macrophage populations to tissue culture flasks. After pelleting and counting BAL cells, cells were resuspended in 7 ml RMPI 1640 medium (Invitrogen, Paisley, United Kingdom) containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 50 g/ml penicillin, 50 g/ml streptomycin, 2 g/ml amphotericin B, and 0.05 M ␤-mercaptoethanol and were seeded into 25-cm 2 tissue culture flasks. After 2 h of incubation at 37°C with 5% CO 2 , nonadherent cells were removed by washing with PBS. This purification method consistently resulted in 96 to 98% pure populations of AMs, as determined by morphological assessment and CD14 staining of cytocentrifuge preparations during preliminary experiments. Adherent cells were trypsinized, washed once with 7 ml fresh medium, and resuspended in 350 l RLT buffer (Qiagen, Crawley, United Kingdom) containing 1% (vol/vol) ␤-mercaptoethanol. Total RNA extraction then was carried out using the RNeasy mini kit (Qiagen), including on-thecolumn digestion of DNA with RNase-free DNase (Qiagen), by following the manufacturer's instructions for animal cells.
RNA extraction from animal tissue. Samples of either lung parenchyma (1 cm 3 ) or lymph node (0.5 cm 3 ) were collected postmortem and stored in RNAlater (Qiagen) at Ϫ80°C prior to RNA extraction using the Fastprep cell disrupter system (Bio 101 Thermoelectron; Qbiogene, Cambridge, United Kingdom). Samples of lung parenchyma (100 mg) or lymph node (20 mg) in 1 ml RLT buffer (Qiagen) containing 1% (vol/vol) ␤-mercaptoethanol were placed in a 2-ml Eppendorf tube containing lysis matrix D (Qbiogene) and pulsed in a Fastprep machine for 40 s. Supernatants then were passed through a Qiashredder column (Qiagen), and total RNA was extracted using the RNeasy mini kit, including on-the-column digestion of DNA with RNase-free DNase (Qiagen), by following the manufacturer's instructions for animal tissues.
Real-time RT-PCR quantitation of AM cytokine gene expression and VMV gag RNA. The relative quantitation of cytokine gene expression and VMV RNA by two-step real-time reverse transcription-PCR (RT-PCR) was performed using the standard curve method. To generate VMV gag RNA standard curves, serial dilutions of plasmid pDS1-gag containing the whole VMV strain EV1 gag gene (provided by Heide Niesalla, University of Edinburgh) were amplified. To generate plasmids for cytokine and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) standard curves, RNA was extracted from in vitro VMV-infected AMs and cDNA was constructed using Superscript II (Invitrogen) and anchored oligo(dT) primers (Sigma) according to the manufacturer's instructions. External primers spanning 300 to 500 bp were used to generate primary PCR products. PCR was carried out with Hot Taq DNA polymerase (Biogene, Kimbolton, United Kingdom) according to the manufacturer's recommendations and using 3 l cDNA and 25 pmol of each primer. Primer sequences and annealing temperatures are shown in Table 1 .
PCR products were purified using the S.N.A.P. UV-free gel purification kit (Invitrogen) and subsequently cloned into the sequencing vector pCR2.1-TOPO (Invitrogen) according to the manufacturer's instructions. Aliquots of each plasmid were sequenced to confirm the presence of the correct insert.
Real-time PCR was performed on cDNA samples using a RotorGene 3000 real-time thermal cycler (Corbett Research, Sydney, Australia) and the appropriate internal primer sets (Table 1) . Cycling was performed in 20-l reaction volumes containing 1 l cDNA, 10 l of 2ϫ Quantitect SYBR green PCR master mix (Qiagen), and 0.5 M of each primer. Thermal cycling parameters involved a 15-min preincubation at 95°C followed by 40 cycles of denaturation at 94°C for 20 s, primer annealing at 52 to 57°C for 20 s, and extension at 72°C for 20 s. Fluorescence data acquisition was performed after each extension step.
Following amplification, a plot of the fluorescence versus the cycle number was generated. The threshold value for each sample was calculated automatically by the RotorGene software (version 5.10) using the fit-point method. Serial 1:10 dilutions of plasmid containing the gene of interest ranging from 10 8 to 10 2 copies per l were run in parallel with each series of samples, allowing the automatic generation of a standard curve by the RotorGene software. The correlation coefficients of standard curves were between 0.98 and 0.99, and PCR efficiencies calculated from the slopes were Ͼ90%. The number of copies per microliter of sample then was calculated for each sample and results were normalized to GAPDH, the expression of which had previously been shown to be unaffected by VMV infection. Standards were run in triplicate, and samples were run in duplicate. Melting curve analysis was performed at the end of each PCR run to verify the specificity of the PCR product.
Immunocytochemistry and histopathology. Selected lung lobes were inflated with a 1:1 mixture of OCT compound (Tissue-Tek; Sakura-Finetek, Zoeterwoude, The Netherlands) before being cut into 1-cm 3 blocks and snap-frozen in isopentane-dry ice. Tissue sections were cut to 6 m thick, mounted on poly-Llysine-coated slides (BDH, Poole, United Kingdom), and stored at Ϫ80°C prior to use.
Immunocytochemical staining was performed on tissue sections and cytocentrifuge slides as previously described (32) using the EnVision Plus HRP system (DakoCytomation, Ely, United Kingdom). Details of monoclonal antibodies (MAbs) used in this study are provided in Table 2 . Cell counts were expressed as the number of positively stained cells per millimeter of bronchiolar epithelium for airways and the number of positively stained cells per square millimeter of lung tissue for lung parenchyma (determined by stereology).
For histopathological analysis, appropriate tissue sections were stained with hematoxylin and eosin. Samples were analyzed blindly by a trained histopathologist, and descriptive qualitative comments on each slide were provided.
Ex vivo infection of AMs with VMV. Immediately after collection, BAL cells were incubated in RMPI 1640 medium (Invitrogen) containing 2 mM L-glutamine and 10% FCS with 1 50% tissue culture infectious dose (TCID 50 )/cell VMV strain EV1 in VueLife 7 tissue culture bags (Cellgenix, Freiburg, Germany) for 2 h. Cell suspensions then were centrifuged at 400 ϫ g for 5 min and resuspended in 25 ml PBS. Cell pellets were washed a further five times in PBS before finally being resuspended in an appropriate volume of PBS. Prior to instillation, viable cell counts were performed using trypan blue exclusion, and differential cytology revealed cell populations to be between 90 and 95% AMs. Aliquots of the last wash were stored at Ϫ80°C for subsequent virus titration to confirm the absence of cell-free virus.
Respiratory tract instillation of cell-free VMV and VMV-infected AMs. For upper respiratory tract instillations of VMV-infected AMs, 1 ϫ 10 6 cells were resuspended in 2 ml PBS, and 1 ml was instilled into each nostril using a modified 8F portex intravenous catheter (Sims Portex Ltd., Hythe, United Kingdom), which resulted in the exposure of the nasal cavity and nasopharynx to instillates, and was shown not to affect AM viability.
Lower respiratory tract instillations of free virus or virus-infected AMs were performed under general anesthesia and delivered via a 21-gauge polyethylene catheter inserted into the lateral channel of a flexible fiber optic bronchoscope (5.3 mm outer diameter) (model FG-16X; Pentax, Englewood, CO). For instillations of cell-free VMV, 2-ml volumes containing 1 ϫ 10 6 TCID 50 VMV were delivered endoscopically into the left cardiac lung lobe. At the same time, an equivalent volume of mock-infected medium control was instilled into a right cardiac lung lobe. For the instillation of VMV-infected AMs, 1 ϫ 10 6 cells in 2 ml PBS were delivered into either the left or right cardiac lung lobes as required, and donor AMs were harvested from either the right or left caudodorsal lobe.
Detection of VMV-specific provirus, transcripts, and serum antibodies. VMV proviral gag DNA in peripheral blood mononuclear cells (PBMCs) was detected by seminested PCR (snPCR) as described previously (33) . Spliced viral transcripts of rev and env genes were detected by RT-snPCR.
For the detection of rev gene transcripts, snPCR of cDNA samples was per-VOL. 82, 2008 ALVEOLAR MACROPHAGES AND VMV TRANSMISSION 1527 formed using the first-round primer pair rev 1 (sense, CAG AGT AAC CTG GAC AGA CA) and rev 3 (antisense, TAT CTG GGT AAA AGT GCG CC) and the second-round primer pair rev 1 and rev 2 (antisense, GTT TTT CCT CGA GGT CCA CA). Both the first-and second-round primer pairs spanned the rev internal splice site of VMV strain EV1 (nucleotide position 6129; accession no. S51392) and generated PCR products of 272 and 189 bp, respectively. RT-snPCR detection of env gene transcripts was performed using the first-round primer pair env 1 (sense, AGA GAA GCG ACG AAA GGA CC) and env 3 (antisense, CCA TTT TTC ACA TGG TTC CC) and the second-round primer pair env 1 and env 2 (antisense, TAC CTG TTA CCA AGC CCT GC). The firstand second-round primer pairs spanned the major splice donor site of EV1 (nucleotide position 319; accession no. S51392). Due to alternative splicing at the 5Ј end of the env gene transcripts, two PCR products were generated for both first-round (354 and 399 bp) and second-round (263 and 308 bp) reactions (accession nos. AM501483 and AM501484, respectively). PCR was carried out using Hot Taq DNA polymerase (Biogene) and 25 pmol of each primer. Five microliters of cDNA was added to first-round reactions, and a 3-l aliquot from the first round of PCR was used in the second-round reaction. Firstand second-round reactions involved 15 and 35 cycles of amplification, respectively.
VMV-specific antibodies in serum were detected using a commercial enzymelinked immunosorbent assay (ELISA) kit (ELITEST-MVV/CAEV; Hyphen Biomed, Neuville sur Oise, France) (37) .
Fluorescent labeling of VMV-infected AMs with PKH26 dye. Cells were fluorescently labeled using a PKH26 red fluorescence cell-linker kit (Sigma, St. Louis, MO) according to the manufacturer's instructions. Prior to the use of labeled cells, viable cell counts were performed using trypan blue exclusion, and a cytocentrifuge preparation of an aliquot of the stained cells was analyzed using F, AAG GCA GAG AAC GGG AAG  366  55  R, AGT GAT GGC GTG GAC AGT  Internal  F, GGT GAT GCT GGT GCT GAG TA  265  57  R, TCA TAA GTC CCT CCA CGA TG  GM-CSF a  NM_001009805  External  F, GCC TGC TTC ACT TCT GGA C  425  55  R, GCT TCT CCT GGG CAC TGT  Internal  F, GAT GGA TGA AAC AGT AGA AGT CG  261  57  R, CAG CAG TCA AAG GGA ATG AT  Tumor necrosis  X55152  External  F, TCC TTG GTG ATG GTT GGT  525  58  factor alpha an MPV II fluorescence microscope (Leitz, Wetzlar, Germany) to assess the intensity and uniformity of staining.
Detection of PKH26-labeled cells. The detection of PKH26-labeled cells after in vivo lung instillation was performed using fluorescence microscopy. At postmortem, BAL was performed on appropriate lung segments, and samples of lung tissue and lymph nodes were collected. Cytocentrifuge slides of BAL cells and sections of lung tissue and lymph nodes were fixed for 5 min in 4% paraformaldehyde in PBS at room temperature. Slides were washed twice in PBS for 3 min each before incubation in 0.5 M glycine in PBS for 5 min at room temperature. After two further PBS washes, slides were incubated in SYBR green (Roche, Mannheim, Germany) diluted 1:20,000 in PBS for 5 min. After a final PBS wash, slides were mounted in Mowiol mounting medium (Calbiochem-Novabiochem, San Diego, CA) and allowed to set for 1 h at room temperature before microscopic analysis using an MPV II fluorescence microscope (Leitz). For cytocentrifuge preparations, a total of 1,000 cells was counted, and the number of PKH26-positive cells was recorded. For tissue samples, a total of 10 sections cut at 100-m intervals was analyzed per sample, and the location of positive cells was recorded.
Sheep. Six Blackface ewes were used to assess the in vivo uptake of cell-free VMV by AMs and subsequent lung inflammatory responses. Suffolk-cross ewes were used to assess both the infectivity of AM-associated VMV in vivo (n ϭ 7) and the migration of VMV-infected AMs after lower lung instillation (n ϭ 7). All sheep were commercially sourced, determined to be free from VMV provirus, and seronegative for VMV-specific antibodies prior to use. All experimental procedures involving animals were approved by The University of Edinburgh's Biological Services Ethical Review Committee and were performed under license as required by the United Kingdom's Animals (Scientific procedures) Act 1986.
Statistical analysis. Data were analyzed for normality of distribution using the Kolmogorov-Smirnov and Anderson-Darling tests. Real-time PCR data, BAL cytology, and immunocytochemical cell counts all were normally distributed, and therefore statistical analyses were performed using paired t tests. P values of Ͻ0.05 were considered significant.
RESULTS

Uptake of cell-free VMV by AMs in vivo.
The lung was classified into various anatomical segments, as shown in Fig. 1 , to allow multiple treatments within the same animal and to provide within-animal control samples. This segmental approach for VMV lung instillation has been described previously (17, 42) . To evaluate the uptake of cell-free VMV by resident lung AMs, 1 ϫ 10 6 TCID 50 of VMV were instilled into the left cardiac lung lobe of six sheep, and at the same time an equivalent volume of mock-infected medium was instilled into the right cardiac lobe. AMs from virus-treated, mock-treated lung lobes and a naive lung lobe (right caudodorsal) were harvested by BAL 7 days postinstillation. Following AM purification, cells were analyzed for the presence of VMV RNA by real-time RT-PCR. Baseline AMs harvested from the relevant lung lobes 7 days preinstillation also were analyzed. Viral gag RNA was detected in AMs from virus-treated lung lobes in all six sheep, with values ranging from 1,000 to 66,000 copies/l cDNA. No viral RNA was detected in AMs purified from mock-infected or nontreated control lung lobes or in AMs purified prior to virus instillation ( Fig. 2A) . GAPDH was detected in all cDNA samples, indicating that RNA extraction and RT were successful for all samples analyzed (data not shown). No dissemination of virus from the virus-treated lung lobes to control lobes was observed 7 days postinfection, validating the segmental approach to VMV lung instillation used in this study.
Spliced viral gene transcripts of both rev and env genes (expressed early and late in the VMV life cycle, respectively [39] ) were detected by RT-snPCR of AMs obtained from virustreated lung lobes in all sheep. For rev PCRs, two PCR products of approximately 190 and 270 bp were generated in all AM samples and positive control cDNA (generated from in vitro- infected OSCs), corresponding to first-and second-round PCR products (Fig. 2B ). Interestingly, env PCR analysis of AM cDNA resulted in the generation of two PCR products of 263 and 308 bp in size, whereas the amplification of positive control cDNA produced only the smaller env PCR product (Fig. 2C) .
The two env transcripts differed by a 45-bp insert located 3Ј to the RNA polymerase II binding site and 5Ј to the start of translation (data not shown). Immunocytochemistry failed to detect any viral capsid protein expression. Therefore, it is concluded that AMs are capable of the uptake of cell-free VMV in vivo and support virus replication to at least the level of late viral gene transcription.
Assessment of lung inflammatory responses during early VMV infection in vivo.
We hypothesized that local inflammatory responses influence initial virus uptake within the lung, either by modulating virus replication within infected cells or by the recruitment of VMV target cells. Following lower lung instillation of 1 ϫ 10 6 TCID 50 of cell-free VMV strain EV1, virus was detected in the blood from 2 to 3 weeks postinstillation (33) . Therefore, key events involved in virus uptake from the lung airspace are likely to occur during this initial 2-to 3-week period. For this reason, lung inflammation was assessed at 7 days postinstillation, a time point within the previremic stage of VMV infection.
BAL cells and lung tissue samples from virus-treated, mocktreated, and naïve lung lobes generated from the above experiment were analyzed using a combination of real-time RT-PCR, cytology of BAL cells, histopathology, and immunocytochemistry. BAL cell populations were analyzed 7 days pretreatment and 7 days posttreatment; lung tissue was analyzed at 7 days posttreatment. As no dissemination of virus from virus-treated lung lobes was evident at 7 days posttreatment, a direct comparison between inflammatory responses in virustreated and control lung lobes could be made for each individual sheep, thus allowing paired statistical analyses of data.
Real-time RT-PCR analysis of cytokine mRNA expression was performed on purified AM populations obtained from VMV-treated, mock-treated, and naïve lung lobes. The results of the analysis of AM cytokine mRNA expression 7 days posttreatment are shown in Fig. 3 . The level of GM-CSF mRNA expression was significantly up-regulated in AMs obtained from virus-treated lung lobes compared to those of AMs from both mock-treated (P Ͻ 0.05) and naïve lung lobes (P Ͻ 0.05) 7 days postinstillation (Fig. 3I) . A significant increase in IL-8 mRNA expression was observed in AMs from virus-treated lung lobes compared to that of AMs from naïve lobes (P Ͻ 0.05) ( Fig. 3C ). However, no significant difference in IL-8 expression was observed between AMs obtained from virustreated and mock-treated lobes. No significant differences in mRNA expression of IL-1␤, IL-6, IL-10, IL-12p40, IL-18, tumor necrosis factor alpha, or tumor growth factor ␤1 were observed between AMs from VMV-treated and mock-treated or naïve lobes. An analysis of cytokine gene expression in pretreatment AM samples and posttreatment lung tissue did not identify any significant differences between virus-treated and control lung lobes (data not shown).
Total BAL cell numbers were within normal limits for all pre-and posttreatment samples, and no significant differences in total cell numbers were observed between lung lobes. The percentages of lymphocytes within posttreatment BAL samples were significantly increased (P Ͻ 0.05) in BAL samples from VMV-treated lung lobes compared to those of BAL samples from posttreatment mock-treated and naïve lung lobes, and they were above normal limits (13.6% Ϯ 4.7% [means Ϯ standard deviations]; normal limits, 3.1% Ϯ 2.0%). The percentages of all other cell types in posttreatment BAL samples and all cell types in pretreatment BAL samples were within normal limits, with no significant differences observed between lobes.
No significant histopathological changes were identified in any lung lobe evaluated. Immunocytochemical analysis of lung tissue failed to identify any significant differences in the numbers of airway or parenchymal major histocompatibility complex class II ϩ , CD1b ϩ , CD4 ϩ , CD8 ϩ , or CD14 ϩ cells between virus-treated, mock-treated, and naïve lung lobes (data not shown).
Infectivity of AM-associated VMV in vivo.
To determine whether AM-associated VMV are infectious in vivo, autologous or heterologous VMV-infected AMs were instilled into either the lower lung or the upper respiratory tract of sheep, and the time taken for viremia and seroconversion to occur was recorded. For lower lung instillations, AMs were harvested from the right caudodorsal lung lobes of two donor Suffolkcross ewes by BAL and subsequently infected with VMV ex vivo. Cells (1 ϫ 10 6 ) were reinstilled into the left cardiac lung lobes of the two donor sheep (autologous instillation), and an identical number of cells were instilled into the same lobe of two further Suffolk-cross ewes (heterologous instillation). For upper respiratory tract instillations, AMs harvested from the right caudodorsal lung lobe of a Suffolk-cross ewe at postmortem subsequently were infected with VMV ex vivo, and 1 ϫ 10 6 cells were instilled into the upper respiratory tract (n ϭ 2) or left cardiac lung lobe (n ϭ 1) of heterologous Suffolk-cross ewes. No virus was detected in samples of the final cell washes prior to instillation, implying that washing had removed viable cell-free VMV. To confirm the successful ex vivo infection of instilled cells, aliquots of each VMV-infected AM preparation were cultured in vitro for 1 week. VMV titers of in vitro culture supernatants 7 days postinfection ranged from 1.1 ϫ 10 5 to 4.0 ϫ 10 6 TCID 50 /ml (Table 3) , and VMV capsid protein was detected exclusively within AM-like cells from all cultures 7 days postinfection (data not shown), indicating successful ex vivo infection. All sheep were bled weekly up to 6 months postinstillation, and blood samples were analyzed for the presence of VMV provirus and anti-VMV antibodies.
The times taken for viremia and seroconversion to occur for each instillation are summarized in Table 3 . Lower lung instillation of autologous VMV-infected AMs resulted in the detection of provirus at 2 weeks postinstillation and seroconversion at 2 to 7 weeks postinstillation. Lower lung instillation of heterologous VMV-infected AMs resulted in the detection of provirus at 2 to 11 weeks postinstillation (mean, 3.6 weeks) and seroconversion at 3 to 17 weeks postinstillation (mean, 7.6 weeks). The same heterologous VMV-infected AM preparation that resulted in successful infection after lower lung instillation failed to result in viremia or seroconversion following upper respiratory tract instillation by 6 months postinstillation. Thus, both autologous and heterologous VMV-infected AMs are infectious in vivo after lower lung instillation. The infectivity of VMV-infected AMs after upper respiratory tract instillation was not demonstrated.
Tracking of VMV-infected AMs after lower lung instillation. The presence of provirus in blood cells following lung instillation of VMV-infected AMs indicated that virus was transferred from AMs in the lung airspace into the body. The mechanism of this virus transfer is unclear. However, it is likely that virus entry involves the infection of draining lymph nodes, which are thought to be an important site of initial infection prior to dissemination throughout the body via the blood (5) .
To determine whether VMV transfer from lung airspace to The results are summarized in Table 4 . Total numbers of cells ranged from 2.6 ϫ 10 5 to 1.6 ϫ 10 7 cells/ml BAL fluid, and results of differential cytology were within normal limits for all BAL samples (data not shown). For the three sheep instilled at two separate time points, cell numbers in 24-h-and 8-daypostinstillation BAL samples were similar for individual sheep. This suggested that no significant cell recruitment had occurred into the bronchoalveolar compartments postinstillation and that the percentage of PKH26 ϩ cells within 24-h and 8-day BAL cell populations could be compared directly. Positive cells were detected in all postinstillation BAL samples by fluorescence microscopy and generally exhibited typical AM morphology (Fig. 4A, B ). No differences in the distribution or intensity of fluorescence staining of positive cells were observed between 24-h-postinstillation samples, 8-day-postinstil-lation samples, or stained cells prior to instillation. The percentage of PKH26 ϩ cells within BAL cell populations ranged from 0.9 to 2.5%, and the percentages of PKH26 ϩ cells within 24-h-and 8-day-postinstillation BAL samples were similar for individual sheep (Table 4 ). PKH26 ϩ cells were present in lung tissue sections and were located within the alveolar airspaces or within the lumen of small and large bronchioles (Fig. 4C,  D) . No PKH26 ϩ cells were seen in negative control lung lobes or in any of the lymph nodes, and no differences in the number or location of PKH26 ϩ cells were detected between autologous and heterologous instillations. In a further attempt to identify PKH26-labeled cells within the draining lymph nodes, fluorescence-activated cell sorting was performed on the disaggregated lymph nodes of sheep W48 and O61 to identify highly fluorescent cells of the same size and complexity as AMs. An analysis of 3 ϫ 10 6 cells from each lymph node failed to identify any positively labeled cells (data not shown).
The results of snPCR analysis of BAL samples and lymph nodes also are shown in Table 4 . VMV provirus was detected in BAL samples from instilled lung lobes but not from negative control lung lobes. Proviral gag DNA was detected in the tracheobronchial lymph nodes of two out of three sheep instilled with autologous AMs and one of three sheep instilled with heterologous AMs, but not in mediastinal or the popliteal lymph nodes. Immunocytochemical analysis for VMV capsid protein was negative for all lung tissue, lymph nodes, and BAL cells (not shown). No proviral DNA was detected in postmortem PBMC samples, and no VMV-specific antibodies were detected in postmortem serum samples.
These results indicate that virus was transferred from infected AMs within the airspace to the tracheobronchial lymph nodes within the first 8 days postinstillation. Furthermore, there was no evidence that infected AMs migrated from the airspace to the draining lymph nodes within this time period, suggesting that this transfer of virus occurred independently of direct cell migration.
DISCUSSION
In this study, it was shown that AMs are capable of the uptake of cell-free VMV after lower lung instillation in vivo. Furthermore, it was demonstrated that autologous VMV-infected AMs are capable of efficiently transmitting virus from the bronchoalveolar space into the body. We have previously shown that a primary mechanism of respiratory transmission of VMV likely involves the inhalation of cell-free VMV and subsequent virus uptake in the lower lung (33) . Therefore, it is possible that the uptake of VMV by resident AMs and the subsequent transfer of virus into the body represent an important route of natural respiratory transmission. The observation that heterologous VMV-infected AMs are capable of transmitting VMV demonstrates for the first time that VMV-infected cells originating from one sheep are capable of infecting another. This was demonstrated only after lower lung instillation of infected cells, suggesting that the upper respiratory tract is relatively insensitive to cell-associated VMV, as is the case for cell-free VMV (46) . As the site of particle deposition in the lung is related to particle size, with larger particles (Ͼ10 m) being preferentially deposited in the upper respiratory tract and only smaller particles (Ͻ5 m) gaining access to the lower airways (20) , it is likely that the majority of inhaled AMs (with average diameters of around 25 m) would be deposited in the upper respiratory tract. However, as it has been demonstrated that a small percentage of larger particles (20 to 30 m) may penetrate the peripheral areas of the lung (13) , it is possible that a small number of inhaled AMs indeed reach the lower lung and subsequently transmit infection. Given the high efficiency of infection following lung instillation of infected AMs demonstrated here, it is possible that a relatively small number of infected AMs could transmit infection. Therefore, the transmission of VMV via the inhalation of infected AMs derived from VMV-infected sheep may represent an additional mechanism of VMV respiratory transmission. Furthermore, as VMV-infected AMs have been identified in the lungs of sheep with no VMV-induced lesions and/or no clinical signs (48) , AM-associated virus transmission may represent a mechanism of transmission during early prelesional and preclinical maedi. The tracking of fluorescently labeled VMV-infected BAL cells after lower lung instillation failed to demonstrate the migration of labeled cells from the bronchoalveolar space up to 8 days postinstillation. Evidence for a lack of cell migration from the lung airspace to the draining lymph nodes was based on two observations. First, labeled cells were not detected within the lung interstitium or lymph nodes. Second, the percentages of positively labeled cells in BAL samples were similar at both 24 h and 8 days postinstillation. The intensity and distribution of the staining of labeled cells at both time points were identical to those of the stained cells preinstillation; this indicated that positive cells detected within the lung airspace had not proliferated within the lung airspace or had been phagocytosed by other resident macrophages. This, therefore, allowed a direct comparison of positive cell counts between samples from the 24-h and 8-day time points, which, given their similarities, suggests that no migration from the airspace had occurred between these two time points. However, we cannot rule out the possibility that some labeled cells migrated immediately (Ͻ24 h) after instillation, or that a small number of labeled cells migrated to the lymph node but remained undetected.
Analysis for VMV identified proviral DNA but not viral protein within labeled cell populations, indicating a typical in vivo-restricted pattern of replication (19, 22) , and demonstrated provirus within the tracheobronchial lymph nodes of sheep 8 days after instillation of both autologous and heterologous VMV-infected AMs. Provirus was present in the draining lymph node at a time comparable to that of a previous study of cell-free VMV transfer from skin to draining lymph nodes, which detected VMV-infected cells within the lymph node from 4 days postinfection, with maximum numbers seen between days 7 and 14 (5) . The lack of evidence for direct cell migration of VMV-infected AMs to this lymph node suggests that virus transport from AMs to the tracheobronchial lymph node occurred via an intermediate route and not by direct cell migration of VMV-infected AMs. There did not appear to be any significant difference in the dynamics of virus transfer to the lymph nodes following instillation of either autologous or heterologous AMs, and this was consistent with our observation that, following instillation of either autologous or heter-ologous VMV-infected AMs, viremia and seroconversion occur at similar time points.
Transfer of virus from AMs to the tracheobronchial lymph node could occur in two ways. First, cell-free virus particles may be released from infected AMs, gain access to the lung interstitium, and travel directly via the afferent lymph to the draining lymph node. Second, VMV may be transferred from AMs to an intermediate cell type that subsequently migrates to the lymph node. A previous study of initial VMV dissemination after intradermal inoculation suggested that of these two possibilities, virus transfer via an intermediate cell type rather than as free virus is most likely: an analysis of afferent lymph draining the virus inoculation sites demonstrated that virus was exclusively cell associated, with no evidence of cell-free VMV within lymph plasma (36) . Furthermore, these VMV-positive cells were shown to be afferent lymph DCs, suggesting that respiratory tract DCs (RTDCs), which are found adjacent to airways in high numbers (32) , play a similar role in virus transfer in the lung.
Both of these mechanisms would require the AMs to be productively infected. The present study found evidence for VMV gag, rev, and env transcript production in AMs following free virus administration and provirus DNA in ex vivo-infected AMs. In contrast, no virus protein could be detected by immunocytochemistry in either case, indicating that the virus in AMs exhibited a typical in vivo-restricted pattern of replication (22) . However, due to a relative lack of sensitivity of the immunocytochemical technique, a small but significant number of AMs may have been productively infected but remained undetected.
Interestingly, PCR analysis of in vivo-infected AMs detected two populations of env gene transcripts generated by alternative splicing, whereas only the smaller env gene transcript was detected in in vitro-infected OSCs. As the two env transcripts differed by an insert 5Ј to the start of translation, the functional significance of this alternative splicing event is unclear, as it would be expected to have no effect on the structure of the translated protein. However, the absence of the larger env transcripts in productively infected OSCs indicates that in these cells at least, the additional 45-bp insert is not required for productive virus replication.
We hypothesized that VMV induces inflammatory responses during initial infection, which subsequently would enhance virus uptake, either by the recruitment of VMV target cells, e.g., RTDCs, or by dysregulation of cytokine gene expression and subsequent enhancement of VMV replication. Therefore, a detailed analysis of lung inflammatory responses during early infection with VMV strain EV1 was undertaken. Up-regulation of AM GM-CSF mRNA expression was observed 7 days after endoscopic instillation of VMV. This finding is consistent with those of previous studies of naturally infected sheep lungs, which demonstrated up-regulation of AM GM-CSF expression in combination with up-regulation of other proinflammatory cytokines and/or observable lung inflammation (29, 50) . AM IL-8 mRNA expression also was increased in virus-treated lung lobes compared to that of untreated lung lobes but not compared to that of mock-treated lobes, suggesting that the IL-8 response either was due to the BAL procedure or was induced by components of the tissue culture medium of virus and mock virus instillates. No changes in AM expression of other proin-flammatory cytokines were observed in this study, and with the exception of an increase in bronchoalveolar lymphocyte populations, analysis of lung tissue failed to demonstrate evidence of lung inflammation. This is in contrast to two previous reports of endoscopic instillation of VMV, which identified extensive inflammatory changes in virus-treated lung lobes after 11 days postinfection (17, 42) . However, in these studies, higher doses of a different strain of virus were used and the sheep were of a different breed, each of which could influence the degree of inflammatory response.
The observations in this study suggest that up-regulation of AM GM-CSF mRNA expression was a specific effect of VMV infection and was not due to the BAL procedure or the tissue culture medium and was not secondary to a generalized inflammatory response. Furthermore, as virus infection after the instillation of cell-free VMV strain EV1 into the lower lung is known to be highly efficient (33) , these results suggest that a generalized inflammatory response is not essential for VMV uptake in the lung. The mechanism(s) by which VMV upregulates AM GM-CSF expression in the absence of inflammation is unclear, although interestingly, up-regulation of this cytokine has been demonstrated in in vitro-cultured AMs in response to inactivated VMV, suggesting that the interaction between virus components and cell surface receptors is sufficient for GM-CSF induction (49) .
The specific increase in bronchoalveloar lymphocyte numbers following VMV instillation is consistent with findings of previous experimental infection studies (2, 8) and, as lymphocyte infiltration is a characteristic of lymphoid interstitial pneumonia, may represent the early stages of VMV-induced pneumonia. How this lymphocyte recruitment is mediated is unclear, but GM-CSF may be involved. It is known that local T-cell responses within the lung are down-regulated by resident AMs (43, 45) and that GM-CSF is capable of abrogating this immunosuppressive activity (3) . Therefore, local GM-CSF production by AMs may result in increased T-cell responses within the bronchoalveolar space, with a resultant increase in lymphocyte numbers. This would be consistent with the observation that GM-CSF appears to be a key driver in lung lesion development in naturally infected sheep (49, 50) .
In addition to playing a potential role in the pathogenesis of lymphoid interstitial pneumonia, up-regulation of GM-CSF expression by AMs in the early stages of infection also may have implications regarding the initial uptake of VMV in the lung. First, it has been demonstrated that GM-CSF enhances VMV replication in monocyte-derived macrophages in vitro (50) . If a similar enhancement occurs in pulmonary macrophages, this could result in increased virus levels within the lung and subsequently may increase virus uptake. Second, as previously discussed, virus uptake from the lung airspace is likely to involve RTDCs. Under steady-state conditions, AMs maintain RTDCs in a down-modulated state (24) . Treatment with GM-CSF has been shown to inhibit this immunosuppressive activity (3, 4) . In addition, GM-CSF has been shown to directly up-regulate the antigen-presenting activity of RTDCs (1, 10) and also has been implicated in RTDC recruitment (44, 47) . Therefore, the up-regulation of GM-CSF expression in AMs may result in the switching of RTDCs toward a more activated phenotype and also recruit RTDCs toward virus-infected AMs, potentially enhancing RTDC uptake of virus within the lung.
Furthermore, it is known that cellular interactions between DCs and CD4 ϩ T cells within the draining lymph nodes are crucial for VMV transfer from DCs to macrophages, which are thought to be the main disseminator of VMV around the body (16) . Therefore, increased activation of RTDCs may result in increased DC-CD4 ϩ T-cell interactions within the lymph nodes with the subsequent enhancement of virus transfer to macrophages. This may in turn lead to increased viral dissemination throughout the body.
In conclusion, this study has demonstrated that resident AM populations within the lung are capable of the uptake of cellfree VMV and that this results in a specific up-regulation of AM GM-CSF expression, which may in turn facilitate virus uptake in the lower lung. Infected AMs were shown to be capable of transmitting virus from the lower lung airspace, but not from the upper respiratory tract, into the body. Furthermore, this transfer of virus did not appear to be mediated by direct cell migration but appeared to involve an intermediate route.
